Is Perspective Therapeutics Inc (AMEX: CATX) Still On The Rise?

After Hours

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Yahoo Finance discussed the stock recently as it posted Perspective Therapeutics Introduces “Pre-Targeting” Theranostic Technology Platform.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Stocks Info

This AMEX-listed company operates within the Medical Devices industry segment, falling under the Healthcare sector. The current market capitalization of Perspective Therapeutics Inc is $420.55M. A total of 2.04 million shares were traded on the day, compared to an average of 1.59M shares.

Insider Activity

Insider trades can also provide insight into a stock’s future direction. During the recent three months, CATX has seen 1 BUY and 0 SELL insider trades, representing the acquisition of 3,663 and the disposition of 0 shares. Over the last 12 months, there were 3 BUYs and 0 SELLs from insiders. Insiders purchased 191,163 shares during that period but sold 0.

In the most recent transaction, Williamson Robert F III bought 127,206 shares of CATX for 0.71 per share on Jan 30. After the transaction, the Director now owns 338,761 company shares. In a previous transaction on Jan 29, Williamson Robert F III bought 25,266 shares at 0.64 per share. CATX shares that Director owns now total 211,555.

Among the insiders who bought shares, Williamson Robert F III acquired of 110,613 shares on Jan 26 at a per-share price of $0.56. This resulted in the Director holding 186,289 shares of CATX after the transaction. In another insider transaction, Williamson Robert F III bought 22,134 shares at $0.49 per share on Jan 25. Company shares held by the Director now total 75,676.

Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for CATX in the last 3 months, the mean price target is $1.33 with high estimates of $1.50 and low estimates of $1.20. In terms of 52-week highs and lows, CATX has a high of $1.00 and a low of $0.20.

As of this writing, CATX has an earnings estimate of $Perspective Therapeutics, Inc. per share for the current quarter. EPS was calculated based on a consensus of Caterpillar, Inc. estimates, with a high estimate of $Calix, Inc per share and a lower estimate of $Cidara Therapeutics, Inc.

Balance Sheet Annually/Quarterly

In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. CATX’s latest balance sheet shows that the firm has $55.89M in Cash & Short Term Investments as of fiscal 2022. There were $524.00k in debt and $2.27M in liabilities at the time. Its Book Value Per Share was $0.35, while its Total Shareholder’s Equity was $61.28M.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CATX is Buy with a score of 5.00.

Most Popular

Related Posts